Who are MEDI3250's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Elrexfio, Elrantamab, HZT-501, BAT1706, BAT2206.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medi3250.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MEDI3250 — Competitive Intelligence Brief

MEDI3250 (MEDI3250) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody; PD-L1/4-1BB bispecific. Area: Oncology.

phase 3 Bispecific antibody; PD-L1/4-1BB bispecific PD-L1 and 4-1BB (CD137) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MEDI3250 (MEDI3250) — AstraZeneca. MEDI3250 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MEDI3250 TARGET	MEDI3250	AstraZeneca	phase 3	Bispecific antibody; PD-L1/4-1BB bispecific	PD-L1 and 4-1BB (CD137)
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrantamab	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)
HZT-501	HZT-501	Amgen	phase 3	Bispecific antibody
BAT1706	BAT1706	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody; PD-L1/4-1BB bispecific class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MEDI3250 — Competitive Intelligence Brief. https://druglandscape.com/ci/medi3250. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab